Saltar al contenido
Merck

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.

Nature communications (2019-09-15)
Patrick L Leslie, Yvonne L Chao, Yi-Hsuan Tsai, Subrata K Ghosh, Alessandro Porrello, Amanda E D Van Swearingen, Emily B Harrison, Brian C Cooley, Joel S Parker, Lisa A Carey, Chad V Pecot
RESUMEN

Lymph node (LN) metastases correspond with a worse prognosis in nearly all cancers, yet the occurrence of cancer spreading from LNs remains controversial. Additionally, the mechanisms explaining how cancers survive and exit LNs are largely unknown. Here, we show that breast cancer patients frequently have LN metastases that closely resemble distant metastases. In addition, using a microsurgical model, we show how LN metastasis development and dissemination is regulated by the expression of a chromatin modifier, histone deacetylase 11 (HDAC11). Genetic and pharmacologic blockade of HDAC11 decreases LN tumor growth, yet substantially increases migration and distant metastasis formation. Collectively, we reveal a mechanism explaining how HDAC11 plasticity promotes breast cancer growth as well as dissemination from LNs and suggest caution with the use of HDAC inhibitors.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fluoruro de fenilmetansulfonilo, ≥98.5% (GC)
Sigma-Aldrich
Anti-vinculina monoclonal antibody produced in mouse, clone hVIN-1, ascites fluid
Sigma-Aldrich
Leupeptin, microbial, ≥90% (HPLC)
Sigma-Aldrich
Trypsin inhibitor from Glycine max (soybean), lyophilized powder
Sigma-Aldrich
Benzamidine, ≥95.0%
Sigma-Aldrich
Benzamidine hydrochloride hydrate, ≥99%
Sigma-Aldrich
Anti-Histone Deacetylase 11 (HDAC11) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution